Wednesday, June 10, 2026
🇺🇸 FDA

Intelligence · Patents

Patents expiring in 2043

Annual patent cliff calendar for 2043 — US pharmaceutical patents by expiration date.

Patents
1,718

Quick answer

1,718 indexed pharmaceutical patents have expiration dates in 2043. Browse by soonest expiry with links to assignee companies and related drugs.

  1. US 11780879

    Inhibition of pulmonary fibrosis with nutlin-3A and peptides

    The Board of Regents of the University of Texas System · Granted Tue Oct 10 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 05 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11780852

    Methods for treating Crohn's disease using 3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile

    Theravance Biopharma R&D IP, LLC · Granted Tue Oct 10 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 05 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11780805

    Carbamoyl phenylalaninol compounds and uses thereof

    AXSOME MALTA LTD. · Granted Tue Oct 10 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 05 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11779657

    Compositions and methods for mitochondrial genome editing

    The Regents of the University of California · Granted Tue Oct 10 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 05 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11779625

    Composition and application thereof in preparing product for protecting mitochondria

    INFINITUS (CHINA) COMPANY LTD. · Granted Tue Oct 10 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 05 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11780904

    Method of producing recombinant high molecular weight vWF in cell culture

    Takeda Pharmaceutical Company Limited · Granted Tue Oct 10 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 05 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11780930

    CD38 modulating antibody

    BLACK BELT THERAPEUTICS LIMITED · Granted Tue Oct 10 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 05 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 2023321198

    Dosage Regimen for a Controlled-Release PTH Compound

    ASCENDIS PHARMA BONE DISEASES AS [DK] · Granted Thu Oct 12 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Oct 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. CA 3255048

    COMPOSITION IMMUNOGÈNE UTILE POUR LA VACCINATION CONTRE LES ROTAVIRUS

    BOEHRINGER INGELHEIM VETMEDICA GMBH [DE] · Granted Thu Oct 12 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Oct 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 11786597

    Ionic liquids for transdermal drug delivery

    The Regents of the University of California · Granted Tue Oct 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 11786608

    Isoquinolinyl triazolone complexes

    Takeda Pharmaceutical Company Limited · Granted Tue Oct 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 11787762

    Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2alpha

    Arcus Biosciences, Inc. · Granted Tue Oct 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 11787778

    Bi-functional compounds and methods for targeted ubiquitination of androgen receptor

    Montelino Therapeutics Inc. · Granted Tue Oct 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 11786591

    Recombinant metapneumovirus F proteins and their use

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Oct 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 11786486

    Pharmaceutical compositions comprising 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione

    PTC THERAPEUTICS, INC. · Granted Tue Oct 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 11787804

    Compositions and methods for modulating hair growth

    The Regents of the University of California · Granted Tue Oct 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 11786548

    Trace element compositions, methods of making and use

    American Regent, Inc. · Granted Tue Oct 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 11786508

    Use of sublingual dexmedetomidine for the treatment of agitation

    BioXcel Therapeutics, Inc. · Granted Tue Oct 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 11787839

    Targeting α2δ-1-bound glutamate receptors for treating diseases and disorders

    The Board of Regents of the University of Texas System · Granted Tue Oct 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 11787796

    Plasma Kallikrein inhibitors and uses thereof

    Takeda Pharmaceutical Company Limited · Granted Tue Oct 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 11787833

    Modified cyclic dinucleoside compounds as sting modulators

    Aligos Therapeutics, Inc. · Granted Tue Oct 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 11786500

    Glutaminase inhibitor therapy

    The Board of Regents of the University of Texas System · Granted Tue Oct 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 11786488

    Dosage forms and methods for enantiomerically enriched or pure bupropion

    AXSOME THERAPEUTICS, INC. · Granted Tue Oct 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 11787771

    Hydrazide containing nuclear transport modulators and uses thereof

    Karyopharm Therapeutics Inc. · Granted Tue Oct 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 11786635

    Extracellular matrix for treating pelvic floor disorders and skeletal muscle degeneration

    The Regents of the University of California · Granted Tue Oct 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 11786606

    Site-specific quantitation of drug conjugations

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Oct 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 11786603

    Optimized transglutaminase site-specific antibody conjugation

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Oct 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 11786602

    ASH1L degraders and methods of treatment therewith

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Oct 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 11786601

    Pegylated capsule-degrading enzyme for the treatment of anthrax

    The Government of the United States of America, as represented by the Secretary of the Navy · Granted Tue Oct 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 11786598

    Lipid formulations for delivery of therapeutic agents

    ARBUTUS BIOPHARMA CORPORATION · Granted Tue Oct 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 11787800

    BRD9 degraders and uses thereof

    FOGHORN THERAPEUTICS INC. · Granted Tue Oct 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 11786560

    Immunoisolation device

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Oct 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 11786554

    Optimized engineered nucleases having specificity for the human T cell receptor alpha constant region gene

    Precision BioSciences, Inc. · Granted Tue Oct 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 11786546

    Compounds and methods for modulating GFAP

    Ionis Pharmaceuticals, Inc. · Granted Tue Oct 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 11786540

    Gliflozins and a method for their delivery during resuscitation from cardiac arrest to improve survival outcomes

    THE UNITED STATES AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS · Granted Tue Oct 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 11786479

    Nucleic acid nanocapsules for drug delivery and targeted gene knockdown

    UNIVERSITY OF CONNECTICUT · Granted Tue Oct 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 11786542

    Methods for enhancing cytotoxic cancer therapy through modulation of purine biosynthesis pathways

    Northwestern University · Granted Tue Oct 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 11786541

    Inhibitor of sphingosine kinase 2 for treating Ebola

    RedHill Biopharma Ltd. · Granted Tue Oct 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 11786532

    2-pyridones and methods of use thereof

    Aligos Therapeutics, Inc. · Granted Tue Oct 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 11787799

    Potent antiviral pyrazolopyridine compounds

    The Regents of the University of California · Granted Tue Oct 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 11786518

    Ophthalmic formulations and uses thereof

    Aldeyra Therapeutics, Inc. · Granted Tue Oct 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 11786502

    Method of treatment

    VANDA PHARMACEUTICALS INC. · Granted Tue Oct 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 11786517

    Methods of treatment using a JAK inhibitor compound

    Theravance Biopharma R&D IP, LLC · Granted Tue Oct 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 11787764

    Heptamethine cyanines for use as fluorescent markers of the biliary and renal systems

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Oct 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 11786524

    Pharmaceutical compounds

    SENTINEL ONCOLOGY LIMITED · Granted Tue Oct 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 11786503

    Pharmaceutical compositions and methods for countering chemotherapy induced cardiotoxicity

    Auransa Inc. · Granted Tue Oct 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 11786539

    Aminoglycoside derivatives and uses thereof in treating genetic disorders

    ELOXX PHARMACEUTICALS LTD. · Granted Tue Oct 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 11786582

    Human application of engineered chimeric antigen receptor (CAR) T-cells

    The Board of Regents of the University of Texas System · Granted Tue Oct 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many pharma patents expire in 2043?

1,718 published patents in our USPTO index have expiration dates falling in calendar year 2043.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.